Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.44 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300320 | 0.84 | SCN9A (0.45) | CHEK1SCN9A | |
| SCHEMBL4175149 | 0.82 | CHEK1 (0.53) | HTR2CCHEK1QDPRTBK1IKBKE | |
| Hydrochloric Acid SCHEMBL4182890 | 0.81 | CHEK1 (0.53) | HTR2CCHEK1QDPRTBK1IKBKE | |
| SCHEMBL23858132 | 0.79 | HTR2C (0.50) | HTR2CQDPRHTR2ATLR9TLR8 | |
| SCHEMBL31342061 | 0.79 | HTR2C (0.47) | HTR2CQDPRHTR2A | |
| SCHEMBL30011155 | 0.79 | HTR2C (0.50) | HTR2CQDPRHTR2ATLR9TLR8 | |
| SCHEMBL13875680 | 0.77 | HTR2C (0.49) | HTR2CQDPR | |
| SCHEMBL4172661 | 0.77 | CHEK1 (0.51) | HTR2CCHEK1QDPRTLR9TLR8 | |
| SCHEMBL18965742 | 0.76 | HTR2C (0.47) | HTR2CQDPRHTR2ATLR9TLR8 | |
| Hydrochloric Acid SCHEMBL4176934 | 0.76 | CHEK1 (0.50) | HTR2CCHEK1QDPRTLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | HTR2C 379/4885CHEK1 4500/4885QDPR 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.